Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over...
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
Prescient Therapeutics (ASX: PTX) Managing Director and CEO Steven Yatomi-Clarke presents at the Switzer Small...
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled...
All the major banks have now lifted interest rates in line with the Reserve Bank...
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.